A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Trifluridine

Nucleoside Analog Antiviral class · 1 generic manufacturer · 1 ANDAs filed at FDA.

First FDA approval2001-05-14
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$2.4M in CY2024 Part D spend16K claims · 12K beneficiaries · 329 plans surveyed

Lowest NADAC
$22.20/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$22.20
Across all dosage forms in distribution.
Highest NADAC
$22.20
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Trifluridine used for?

Trifluridine is a Nucleoside Analog Antiviral medication tracked in Medicare Part D.

Is there a generic for Trifluridine?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Trifluridine?

Across 329 Part D plans, Trifluridine averages $22.20/unit (NADAC). Lowest available: $22.20/unit. Highest in distribution: $22.20/unit.

Is Trifluridine on the FDA shortage list?

No. Trifluridine is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Nucleoside Analog Antiviral2 alternatives in D1
01
Ribavirin
Brand: Virazole
Lowest NADAC
4Generic mfrs
$413,762CY24 Part D spend
Compare →
02
Trifluridine and Tipiracil
Brand: LONSURF
Lowest NADAC
2Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.